News

Fintel reports that on June 28, 2024, B of A Securities initiated coverage of CG Oncology (NasdaqGS:CGON) with a Buy recommendation.

Analyst Price Forecast Suggests 120.56% Upside

As of June 12, 2024, the average one-year price target for CG Oncology is 69.56. The forecasts range from a low of 50.50 to a high of $90.30. The average price target represents an increase of 120.56% from its latest reported closing price of 31.54.

See our leaderboard of companies with the largest price target upside.

The projected annual revenue for CG Oncology is 1MM, an increase of 89.24%. The projected annual non-GAAP EPS is -1.68.

What is the Fund Sentiment?

There are 225 funds or institutions reporting positions in CG Oncology. This is an increase of 213 owner(s) or 1,775.00% in the last quarter. Average portfolio weight of all funds dedicated to CGON is 0.93%, an increase of 362.21%. Total shares owned by institutions increased in the last three months by 5,603.09% to 41,142K shares.

The put/call ratio of CGON is 2.66, indicating a bearish outlook.

What are Other Shareholders Doing?

Decheng Capital holds 5,459K shares representing 8.19% ownership of the company.

TCG Crossover Management holds 3,570K shares representing 5.36% ownership of the company.

Bvf holds 1,884K shares representing 2.83% ownership of the company.

Janus Henderson Group holds 1,521K shares representing 2.28% ownership of the company.

Avidity Partners Management holds 1,455K shares representing 2.18% ownership of the company.

Fintel is one of the most comprehensive investing research platforms available to individual investors, traders, financial advisors, and small hedge funds.

Our data covers the world, and includes fundamentals, analyst reports, ownership data and fund sentiment, options sentiment, insider trading, options flow, unusual options trades, and much more. Additionally, our exclusive stock picks are powered by advanced, backtested quantitative models for improved profits.

Click to Learn More

This story originally appeared on Fintel.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.